Skip to content

Efficacy and safety of combination of dapoxetine and acupuncture versus dapoxetine monotherapy in the treatment of lifelong premature ejaculation

Efficacy and safety of combination of dapoxetine and acupuncture versus dapoxetine monotherapy in the treatment of lifelong premature ejaculation

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-ICR-15007004
Enrollment
Unknown
Registered
2015-05-08
Start date
2015-09-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Premature Ejaculation

Interventions

Group A:dapoxetine and acupuncture
Group B:daboxiting+simulative acupuncture

Sponsors

The first affiliated hospital of Anhui medical university
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. male patient aged >=18 years; 2. in a heterosexual, stable, and monogamous sexual relationship with the same female partner for >6 months, 3. possible sexual attempts of once a week or more; 4. with an International Index of Erectile Function-5 (IIEF-5) score >=22, indicating normal erectile function.

Exclusion criteria

Exclusion criteria: 1. with any concomitant diseases, such as hyperthyroidism, diabetes, heart disease,hyperthyroidism,etc. 2. with other urinary diseases,such as prostatic inflammation, urinary system infection,etc. 3. with a history of psychological diseases, 4. known hypersensitivity to selective serotonin reuptake inhibitors(SSRIs) or concomitant use of SSRIs, tricyclic antidepressants, or other medications during the study. Patients with previous therapies of PE, including psychological or medical, were excluded from the study.

Design outcomes

Primary

MeasureTime frame
IELT;PEDT;PEP;

Countries

China

Contacts

Public ContactXiansheng Zhang
xiansheng-zhang@163.com+86 0551 62922046

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026